文献速递心脑血管急症重症综合管理与镇静镇痛

院外心脏骤停患者治疗性低温中复温时长与神经功能结局的关联

Association between rewarming duration and neurological outcome in out-of-hospital cardiac arrest patients receiving therapeutic hypothermia.
PubMed 文献 · Resuscitation · 2019-08-05
一句话结论在院外心脏骤停接受治疗性低温(目标34°C)的患者中,复温时长每延长5小时,出院时不良神经功能结局的比值独立降低(OR 0.89,95%CI 0.79–0.99,p=0.032)。

本研究为J-PULSE-HYPO研究登记库的二次分析,该登记库为多中心前瞻性队列研究,纳入2005至2011年日本14家医院中院外心脏骤停后恢复自主循环并接受治疗性低温(目标温度34°C)的患者,共分析328例。复温时长定义为从34°C开始复温至达到36°C的时间。主要结局为出院时不良神经功能结局(脑功能分级3–5级)。多变量logistic回归显示,复温时长与不良神经功能结局独立相关(每5小时OR 0.89,95%CI 0.79–0.99,p=0.032)。作者结论认为,较长的复温时长与 favorable 神经功能结局显著相关,且为其独立预测因素。

要点

  • 在院外心脏骤停接受治疗性低温(目标34°C)的患者中,复温时长每延长5小时,出院时不良神经功能结局的比值独立降低(OR 0.89,95%CI 0.79–0.99,p=0.032)。
  • 复温时长定义为从34°C开始复温至达到36°C的时间;本研究人群中复温时长范围从不足24小时至超过50小时。
  • 欧洲复苏委员会指南推荐院外心脏骤停治疗性低温患者的复温速率为0.25°C/h–0.5°C/h;日本通常采用非常缓慢的复温(1°C/天)。
  • 主要结局为出院时脑功能分级3–5级(不良神经功能结局);328例分析患者中79.9%存活至出院,其中56.4%神经功能结局良好。
  • 目前尚无随机对照试验检验院外心脏骤停治疗性低温的最佳复温速度。

适用人群与场景

  • 院外心脏骤停后恢复自主循环并接受治疗性低温(目标温度34°C)的患者。
  • 数据来自2005至2011年日本14家医院的多中心前瞻性队列研究(J-PULSE-HYPO研究登记库)。

诊断标准与关键阈值

  • 复温时长定义:从34°C开始复温至达到36°C的时间。
  • 主要结局:出院时脑功能分级(cerebral performance category)3–5级定义为不良神经功能结局。

处置流程与药物剂量

  • 治疗性低温目标温度为34°C。
  • 欧洲复苏委员会指南推荐院外心脏骤停治疗性低温患者的复温速率为0.25°C/h–0.5°C/h。
  • 日本通常采用非常缓慢的复温(1°C/天)。
  • 本研究人群中复温时长范围从不足24小时至超过50小时。

研究设计与关键结果

  • 研究类型:J-PULSE-HYPO研究登记库的二次分析,该登记库为多中心前瞻性队列研究;纳入2005至2011年日本14家医院的院外心脏骤停接受治疗性低温(目标温度34°C)患者。
  • J-PULSE-HYPO研究共纳入452例院外心脏骤停患者,其中328例纳入分析;79.9%存活至出院,存活者中56.4%神经功能结局良好。
  • 多变量logistic回归分析显示,复温时长与不良神经功能结局独立相关(每5小时OR 0.89,95%CI 0.79–0.99,p=0.032)。
  • 作者结论:较长的复温时长与 favorable 神经功能结局显著相关,且为独立预测因素。

证据类型、等级与局限

  • 证据类型:多中心前瞻性队列研究的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 本研究提示,在院外心脏骤停接受治疗性低温(目标34°C)的患者中,较长的复温时长与较好的出院神经功能结局独立相关;原文未据此给出推荐。

指南或共识出处

  • 欧洲复苏委员会指南推荐院外心脏骤停治疗性低温患者的复温速率为0.25°C/h–0.5°C/h。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

AIM: The European Resuscitation Council guidelines recommend a slow rate of rewarming of 0.25 °C/h-0.5 °C/h for out-of-hospital cardiac arrest (OHCA) patients receiving therapeutic hypothermia (TH). Conversely, a very slow rewarming of 1 °C/day is generally applied in Japan. The rewarming duration ranged from less than 24 h up to more than 50 h. No randomized control trials have examined the optimal rewarming speed for TH in OHCA patients. Therefore, we examined the association between the rewarming duration and neurological outcomes in OHCA patients who received TH.

METHODS: This study was a secondary analysis of the Japanese Population-based Utstein-style study with defibrillation and basic/advanced Life Support Education and implementation-Hypothermia (J-PULSE-HYPO) study registry, a multicenter prospective cohort study. Patients suffering from OHCA who received TH (target temperature, 34 °C) after the return of spontaneous circulation from 2005 to 2011 in 14 hospitals throughout Japan were enrolled. The rewarming duration was defined as the time from the beginning of rewarming at a target temperature of 34 °C until reaching 36 °C. The primary outcome was an unfavorable neurological outcome at hospital discharge, i.e., a cerebral performance category of 3-5.

RESULTS: The J-PULSE-HYPO study enrolled 452 OHCA patients. Of these, 328 were analyzed; 79.9% survived to hospital discharge, of which 56.4% had a favorable neurological outcome. Multivariable logistic regression analysis revealed that the rewarming duration was independently associated with unfavorable neurological outcomes [odds ratio (per 5 h), 0.89; 95% confidence interval, 0.79-0.99; p = 0.032].

CONCLUSION: A longer rewarming duration was significantly associated with and was an independent predictor of favorable neurological outcomes in OHCA patients who received TH.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Hifumi T, Inoue A, Kokubu N, et al. Association between rewarming duration and neurological outcome in out-of-hospital cardiac arrest patients receiving therapeutic hypothermia. Resuscitation. 2019. PMID: 31394154. doi:10.1016/j.resuscitation.2019.07.029

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。